Xigen Overview

  • Founded
  • 2002
  • Status
  • Out of Business
  • Employees
  • 6
  • Latest Deal Type
  • Out of Business

Xigen General Information


Developer of innovative therapeutic peptides intended to use it against inflammation. The company's peptides have metabolic stability, specificity and are selectively delivered to intracellular targets through proprietary carrier molecules, enabling physicians to treat a broad range of diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Route de la corniche 4
  • 1066 Épalinges
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 000.00 Completed Out of Business
4. Later Stage VC (Series B) 16-Nov-2009 0000 000.00 Completed Generating Revenue
3. Secondary Transaction - Private 01-Jan-2008 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 06-Sep-2005 $20.7M $20.7M Completed Generating Revenue
1. Angel (individual) 19-Jan-2004 Completed Generating Revenue
To view Xigen’s complete valuation and funding history, request access »

Xigen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial